Modelling drug transport during intraperitoneal chemotherapy

Abstract Despite a strong rationale for intraperitoneal (IP) chemotherapy, the actual use of the procedure is limited by the poor penetration depth of the drug into the tissue. Drug penetration into solid tumours is a complex mass transport process that involves multiple parameters not only related to the used cytotoxic agent but also to the tumour tissue properties and even the therapeutic setup. Mathematical modelling can provide unique insights into the different transport barriers that occur during IP chemotherapy as well as offer the possibility to test different protocols or drugs without the need for in vivo experiments. In this work, a distinction is made between three different types of model: the lumped parameter model, the distributed model and the cell-based model. For each model, we discuss which steps of the transport process are included and where assumptions are made. Finally, we focus on the advantages and main limitations of each category and discuss some future perspectives for the modelling of IP chemotherapy.

[1]  Jerry Goodisman,et al.  Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[2]  Greg M. Thurber,et al.  Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo , 2013, Nature Communications.

[3]  Chi-Hwa Wang,et al.  Chemotherapeutic drug transport to brain tumor. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[4]  M F Flessner,et al.  A distributed model of peritoneal-plasma transport: theoretical considerations. , 1984, The American journal of physiology.

[5]  Beom Soo Shin,et al.  Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy , 2009, Journal of Pharmacology and Experimental Therapeutics.

[6]  Jörgen Carlsson,et al.  Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids , 2004, Cancer Chemotherapy and Pharmacology.

[7]  J. Verweij,et al.  Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion. , 1994, British Journal of Cancer.

[8]  Ze Lu,et al.  Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel , 2007, Pharmaceutical Research.

[9]  M D'Incalci,et al.  Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer , 2014, British Journal of Cancer.

[10]  Robert J. Gillies,et al.  Current Advances in Mathematical Modeling of Anti-Cancer Drug Penetration into Tumor Tissues , 2013, Front. Oncol..

[11]  Masaki Kitajima,et al.  Antitumor activity of cis‐diamminedichloroplatinum (II) depends on its time × concentration product against human gastric cancer cell lines in vitro , 1995, Journal of surgical oncology.

[12]  Donald E Mager,et al.  Systems Pharmacological Analysis of Paclitaxel-Mediated Tumor Priming That Enhances Nanocarrier Deposition and Efficacy , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[13]  S Pili-Floury,et al.  Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study , 2011, British Journal of Cancer.

[14]  Vittorio Cristini,et al.  Multiscale cancer modeling. , 2010, Annual review of biomedical engineering.

[15]  Yuichi Sugiyama,et al.  Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product , 2004, Cancer Chemotherapy and Pharmacology.

[16]  Chi-Hwa Wang,et al.  Simulation of the Delivery of Doxorubicin to Hepatoma , 2001, Pharmaceutical Research.

[17]  An Vermeulen,et al.  A Model Based Analysis of IPEC Dosing of Paclitaxel in Rats , 2014, Pharmaceutical Research.

[18]  R K Jain,et al.  Haemodynamic and transport barriers to the treatment of solid tumours. , 1991, International journal of radiation biology.

[19]  Jacek Waniewski,et al.  Computer simulations of osmotic ultrafiltration and small-solute transport in peritoneal dialysis: a spatially distributed approach. , 2012, American journal of physiology. Renal physiology.

[20]  Ze Lu,et al.  Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer , 2008, Journal of Pharmacology and Experimental Therapeutics.

[21]  H. Kampinga,et al.  Reduction of cellular cisplatin resistance by hyperthermia--a review. , 1997, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[22]  H. Eichholtz-Wirth,et al.  Heat sensitization to cisplatin in two cell lines with different drug sensitivities. , 1990, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[23]  M. Flessner,et al.  The transport barrier in intraperitoneal therapy. , 2005, American journal of physiology. Renal physiology.

[24]  W R Greco,et al.  Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. , 1998, Cancer research.

[25]  R. Dedrick,et al.  Theoretical and experimental bases of intraperitoneal chemotherapy. , 1985, Seminars in oncology.

[26]  Véronique Préat,et al.  Topical Gene Transfer into Rat Skin Using Electroporation , 2004, Pharmaceutical Research.

[27]  Chi-Hwa Wang,et al.  Computer simulation of the delivery of etanidazole to brain tumor from PLGA wafers: comparison between linear and double burst release systems. , 2003, Biotechnology and bioengineering.

[28]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[29]  Spyros K. Stamatelos,et al.  Multiscale Imaging and Computational Modeling of Blood Flow in the Tumor Vasculature , 2012, Annals of Biomedical Engineering.

[30]  Timothy W Secomb,et al.  A mathematical model for cisplatin cellular pharmacodynamics. , 2003, Neoplasia.

[31]  G. Bonadonna,et al.  Chemotherapy of malignant lymphomas. , 1985, Seminars in oncology.

[32]  R K Jain,et al.  Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. , 1989, Microvascular research.

[33]  H. Skipper,et al.  The effects of chemotherapy on the kinetics of leukemic cell behavior. , 1965, Cancer research.

[34]  A. Einstein Über die von der molekularkinetischen Theorie der Wärme geforderte Bewegung von in ruhenden Flüssigkeiten suspendierten Teilchen [AdP 17, 549 (1905)] , 2005, Annalen der Physik.

[35]  Ze Lu,et al.  Multiscale Tumor Spatiokinetic Model for Intraperitoneal Therapy , 2014, The AAPS Journal.

[36]  Stephen Clarke,et al.  Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer Chemotherapeutics , 2012, Clinical Pharmacokinetics.

[37]  M F Flessner,et al.  A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. , 1985, The American journal of physiology.

[38]  Byungkyu Kim,et al.  Cell Stiffness Is a Biomarker of the Metastatic Potential of Ovarian Cancer Cells , 2012, PloS one.

[39]  C. Erlichman,et al.  Antineoplastic drug cytotoxicity in a human bladder cancer cell line: Implications for intravesical chemotherapy , 1987, Urological Research.

[40]  J. Robinson,et al.  Theoretical formulation of sustained-release dosage forms. , 1966, Journal of pharmaceutical sciences.

[41]  Yasunari Miyagi,et al.  Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai , 2005, Gynecologic oncology.

[42]  J G McVie,et al.  Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. , 1990, Cancer chemotherapy and pharmacology.

[43]  Urs Giger-Pabst,et al.  Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy , 2013, Annals of Surgical Oncology.

[44]  P. Sugarbaker,et al.  Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics , 2003, Cancer Chemotherapy and Pharmacology.

[45]  M. Wientjes,et al.  Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. , 2001, The Journal of pharmacology and experimental therapeutics.

[46]  S N Gardner,et al.  A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. , 2000, Cancer research.

[47]  Mahadevabharath R. Somayaji,et al.  Prediction of convection-enhanced drug delivery to the human brain. , 2008, Journal of theoretical biology.

[48]  H. Bartelink,et al.  Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. , 1998, European journal of cancer.

[49]  Michel Simonet,et al.  High Intra-abdominal Pressure Enhances the Penetration and Antitumor Effect of Intraperitoneal Cisplatin on Experimental Peritoneal Carcinomatosis , 2006, Annals of surgery.

[50]  Abbas Shirinifard,et al.  Ovarian Tumor Attachment, Invasion, and Vascularization Reflect Unique Microenvironments in the Peritoneum: Insights from Xenograft and Mathematical Models , 2013, Front. Oncol..

[51]  S P Eriksen,et al.  Mathematical model of sustained-release preparations and its analysis. , 1966, Journal of pharmaceutical sciences.

[52]  G Milano,et al.  Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration. , 1992, European journal of cancer.

[53]  Wilson Mok,et al.  Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo. , 2009, Biophysical journal.

[54]  James A Glazier,et al.  Multicell simulations of development and disease using the CompuCell3D simulation environment. , 2009, Methods in molecular biology.

[55]  A. Oka,et al.  Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. , 1996, British Journal of Cancer.

[56]  Kimberly R. Kanigel Winner,et al.  Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer. , 2016, Cancer research.

[57]  N. Forbes,et al.  Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response , 2010, British Journal of Cancer.

[58]  Patrick Segers,et al.  Mathematical modeling of intraperitoneal drug delivery: simulation of drug distribution in a single tumor nodule , 2017, Drug delivery.

[59]  Jesús A. Izaguirre,et al.  From Genes to Organisms Via the Cell: A Problem-Solving Environment for Multicellular Development , 2007, Computing in Science & Engineering.

[60]  Y. Maehara,et al.  Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxicity and intracellular platinum accumulation in HeLa cells. , 1993, British Journal of Cancer.

[61]  Timothy W Secomb,et al.  A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. , 2004, Neoplasia.

[62]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[63]  Min Wu,et al.  The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. , 2013, Journal of theoretical biology.

[64]  Michael J Cima,et al.  Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[65]  Michael F. Flessner,et al.  Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence , 2010, Nature Reviews Clinical Oncology.

[66]  V. Devita,et al.  Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. , 1978, Cancer treatment reports.

[67]  Christian Vanhove,et al.  Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model , 2015, Oncotarget.

[68]  S. Bigler,et al.  Is the Peritoneum a Significant Transport Barrier in Peritoneal Dialysis? , 2003, Peritoneal Dialysis International.

[69]  Paolo P. Provenzano,et al.  Collagen reorganization at the tumor-stromal interface facilitates local invasion , 2006, BMC medicine.